CAS
IMDX

Coppell Advisory Solutions’s Insight Molecular Diagnostics IMDX Stock Holding History

Coppell Advisory Solutions’s Portfolio IMDX Stock Details IMDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-10
Closed -$24 – 1360
2024
Q4 		$24 Hold
10
– – ﹤0.01% 1954
2024
Q3 		$29 Hold
10
– – ﹤0.01% 1849
2024
Q2 		$30 Buy
+10
New +$27 ﹤0.01% 1769
2023
Q4 		$25 Buy
+10
New +$31 ﹤0.01% 1695
2023
Q3 		– Sell
-10
Closed -$44 – 1442
2023
Q2 		$44 Buy
+10
New +$50 ﹤0.01% 1401

Other funds holding IMDX

BC
Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return
AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return
PVI
Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
WIA
Wealthedge Investment Advisors New York $294M AUM 20.18% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Coppell Advisory Solutions's IMDX Position: Q1 2025 in Review

Coppell Advisory Solutions sold out of Insight Molecular Diagnostics (IMDX) in Q1 2025, closing a stake of 10 shares — an estimated $24 sold.

Coppell Advisory Solutions first reported a position in IMDX in Q2 2023 and held it in 5 quarters. The position peaked at $44 in Q2 2023. 30 funds tracked by Wall St. Rank hold IMDX as of Q1 2025.

  • Coppell Advisory Solutions reported no remaining Insight Molecular Diagnostics position as of Q1 2025 after selling out during the quarter.
  • Coppell Advisory Solutions sold 10 Insight Molecular Diagnostics shares in Q1 2025, an estimated $24.
  • Coppell Advisory Solutions first reported a position in Insight Molecular Diagnostics in Q2 2023 and held it in 5 quarters.
  • Coppell Advisory Solutions's Insight Molecular Diagnostics position peaked at $44 in Q2 2023.
  • 30 funds tracked by Wall St. Rank held Insight Molecular Diagnostics as of Q1 2025.

Based on Coppell Advisory Solutions's 13F filing for Q1 2025, filed 16 May 2025.